FBFlorian Brandt

Florian Brandt

*This is an algorithmically generated author record based on publicly available information.

Florian Brandt has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A web-based knowledge database to provide evidence-based information to cancer patients: Utilization within the PIKKO study

    by Nico Schneider, Uwe Altmann, Florian Brandt, Jutta Hübner, Bernhard Strauss, Christian Keinki

    Purpose: Cancer is associated with an urgent need for understandable and reliable information, which is often not satisfied by information available online. Therefore, as part of the PIKKO project, a web-based knowledge database (WDB) was introduced to provide cancer patients with quality-assured, evidence-based information. This paper aims to provide insights into the usage (Who? How? What?) and the effects regarding health literacy of the WDB. Methods: A patient survey and automatically generated logfile data were evaluated. Two user groups, patients and patient navigators (PNs), were compared. Results: The 13 PNs were responsible for 1/3 of all accesses over the entire duration of the project. The 413 patients used WDB twice on average and spent an average of 12 min per session online (PNs: 9 min per session, more frequently). The top 3 topics of interest were ‘therapy’, ‘nutrition’ and ‘carcinogenesis’ for the patients, and ‘therapy’, ‘naturopathy’ and ‘legal regulations/support’ for the PNs. Of the patients surveyed, 69% said that WDB was helpful in making informed decisions, 76% found the information they wanted and 90% thought WDB was an appropriate way to provide information. Conclusion: Our WDB provided important information about cancer and its treatment on a digital way both, to patients and PNs. In routine cancer care, the WDB can improve health literacy and informed decision-making. Trial registration: This study was retrospectively registered in the German Clinical Trial Register under DRKS00016703 (21 Feb 2019, retrospectively registered). https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00016703


  • Open Access

    COVID-19-associated costs and mortality in Germany: an incidence-based analysis from a payer’s perspective

    by Florian Brandt, Giancarlo Simone, Jörg Loth, Daniel Schilling

    Background: This study aims to estimate average COVID-19-associated healthcare costs per capita in Germany from a payer perspective. In addition, insights into COVID-19-associated mortality should be gained. Methods: For this purpose, a retrospective longitudinal analysis using health insurance claims data was performed. Patients affected by COVID-19 in Q1/2021 (investigation group (IG)) were compared to a matched non-COVID-19 control group (CG) (1:1 propensity score matching (PSM)). Mean values of healthcare costs in 2020 and 2021 were computed for both groups and then separated by age and by development of Post-COVID-19 Syndrome (PCS). Group differences were examined using Mann–Whitney U test (α = 0.05). Difference-in-Differences approach (DiD) was used to estimate average cost effects of COVID-19 in 2021. Concerning mortality, the number of deaths in 2021 was compared between IG and CG using χ2 test of independence. Results: A total of 8,014 insurants were included (n = 4,007 per group; n = 536 per group examining PCS patients only). Total healthcare costs varied a lot in the sample, were comparable between IG and CG in 2020, but were significantly higher in the IG in 2021 (DiD estimate = € 1,063 (in total); € 3,242 (PCS group)). This was more pronounced in the older age groups. High hospital costs of a minority of patients were the most influential driver of COVID-19-associated healthcare costs. Mortality was more than doubled in the IG (tripled in patients aged ≥ 60). Conclusions: COVID-19 is associated with significantly increased healthcare costs and mortality, especially in older age groups. The additional development of PCS further increases the costs of COVID-19.


  • Open Access

    Smartphonebasiertes Screening auf Vorhofflimmern: Erkenntnisse der eBRAVE-AF-Studie

    by Florian Brandt, Ikk Südwest, Christoph Eisert, Axel Bauer, Preventicus GmbH, Kardiologie Und Angiologie Universitätsklinik Für Innere Medizin Iii

    Vorhofflimmern (VHF) ist die häufigste relevante Herzrhythmusstörung und kann zu schweren Folgeerkrankungen führen. Beispielsweise führt unerkanntes und nicht therapiertes VHF zu einem deutlichen Anstieg des Schlaganfallrisikos. Derartigen Risiken kann durch Behandlung mit blutverdünnenden Medikamenten – der sogenannten oralen Antikoagulation (OAK) – entgegengewirkt werden. Oftmals wird VHF jedoch nicht rechtzeitig erkannt. Smartphone-basierte Screenings bieten einen niedrigschwelligen und skalierbaren Ansatz, diesem Problem zu begegnen. Im Rahmen der randomisierten kontrollierten eBRAVE-AF-Studie wurde ein solcher unter 5.551 Risikopatient:innen untersucht. In einer ersten Studienphase durchliefen 2.860 Teilnehmer:innen (Interventionsgruppe) ein Screening-Programm, das eine Screening-App, ein angeschlossenes telemedizinisches Zentrum sowie – im Falle einer auffälligen App-Messung – ein 14-Tage-EKG umfasste, während weitere 2.691 :innen (Kontrollgruppe) regulär versorgt wurden. Nach sechs Monaten wechselte die Gruppenzugehörigkeit (Cross-Over-Design) und es schloss sich eine zweite, sechsmonatige Studienphase an. Mithilfe des Screening-Programms konnte die Erkennungsrate von behandlungsbedürftigem VHF in beiden Phasen mehr als verdoppelt werden. Dieser Studienbericht gibt hierin und in weitere Erkenntnisse einen näheren Einblick.

  • Open Access

    Patient information, communication and competence empowerment in oncology: Results and learnings from the PIKKO study

    by Nico Schneider, Anna Bäcker, Bernhard Strauss, Jutta Hübner, Sabine Rubai, Steffen Wagner, Doris Schwarz-Fedrow, Lutz Hager, Katja Brenk-Franz, Christian Keinki, et al.

    Purpose: Many concepts for accompanying and supporting cancer patients exist and have been studied over time. One of them was PIKKO (a German acronym for “Patient information, communication and competence empowerment in oncology”), which combined a patient navigator, socio-legal and psychological counseling (with psychooncologists), courses dealing with various supportive aspects, and a knowledge database with validated and easy-to-understand disease-related information. The aim was to increase the patients' health-related quality of life (HRQoL), self-efficacy as well as health literacy and to reduce psychological complaints such as depression and anxiety. Methods: To this purpose, an intervention group was given full access to the modules in addition to treatment as usual, while a control group received only treatment as usual. Over twelve months, each group was surveyed up to five times. Measurements were taken using the SF12, PHQ-9, GAD, GSE, and HLS-EU-Q47. Results: No significant differences were found in scores on the mentioned metrics. However, each module was used many times and rated positively by the patients. Further analyses showed a tendency higher score in health literacy with higher intensity of use of the database and higher score in mental HRQoL with higher intensity of use of counseling. Conclusion: The study was affected by several limitations. A lack of randomization, difficulties in recruiting the control group, a heterogeneous sample, and the COVID-19 lockdown influenced the results. Nevertheless, the results show that the PIKKO support was appreciated by the patients and the lack of measurable effects was rather due to the mentioned limitations than to the PIKKO intervention. Trial registration: This study was retrospectively registered in the German Clinical Trial Register under DRKS00016703 (21.02.2019, retrospectively registered). https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00016703


  • Psychometrische Eigenschaften des Qualiskope-A zur Messung der Patientenzufriedenheit mit der ambulant-ärztlichen Behandlung: Einsatz in der Onkologie und Übertragbarkeit auf die stationäre Versorgung

    by Florian Brandt, Nico Schneider, Uwe Altmann, Bernhard Strauß, Jutta Hübner, Christian Keinki

    Zielsetzung Das Qualiskope-A ist ein deutschsprachiger Patientenfragebogen, der – mit Hilfe von 27 Items verteilt auf vier Skalen – eine Messung der Patientenzufriedenheit mit der ambulant-ärztlichen Behandlung ermöglicht. In dieser Studie wurde untersucht, ob der Fragebogen auch in einer onkologischen Population zuverlässige Ergebnisse liefert und ob sein Anwendungsbereich auf die stationäre Versorgung ausgeweitet werden kann. Methodik Die erforderlichen Daten wurden im Rahmen der PIKKO-Studie erhoben. Zunächst wurden deskriptive Skalenstatistiken und interne Konsistenz (Cronbachs Alpha) analysiert. Zusätzlich wurde eine Teilstichprobe, die zu zwei aufeinanderfolgenden Messzeitpunkten denselben Arzt bewertete, hinsichtlich Retest-Reliabilität betrachtet (Spearman Korrelation (rs) zwischen den Messzeitpunkten). Anschließend wurde das Messmodell des Qualiskope-A mittels konfirmatorischer Faktorenanalyse untersucht. Zur Prüfung der Übertragbarkeit auf die stationäre Versorgung wurde die Messinvarianz hinsichtlich ambulant und stationär behandelter Patienten berechnet. Ergebnisse In die Untersuchung wurden n=476 Patienten eingeschlossen. Alle Scores des Qualiskope-A wiesen in der Stichprobe eine stark linksschiefe Verteilung auf und ließen ausgeprägte Deckeneffekte erkennen. Für Cronbachs Alpha galt durchweg > 0,8. In der Retest-Gruppe (n=197) war eine starke Korrelation (rs>0,5) zwischen den Messzeitpunkten zu beobachten. Die mittels konfirmatorischer Faktorenanalyse berechneten Fit-Indizes belegten einen guten Modellfit (CFI=0,958; RMSEA=0,026; SRMR=0,040; alle Faktorladungen>0,6). Die im Rahmen der Untersuchung der Messinvarianz berechneten Fit-Indizes erfüllten durchweg die definierten Schwellenwerte. Schlussfolgerung Das Qualiskope-A weist in der untersuchten onkologischen Stichprobe eine gute Reliabilität auf. Es kann sowohl im ambulanten, als auch im stationären Setting eingesetzt werden (Hinweise auf Non-Invarianz fanden sich nicht). Aufgrund ausgeprägter Deckeneffekte sollte jedoch die Itemskalierung überarbeitet werden. Aim The Qualiskope-A is a German-language PREM (Patient Reported Experience Measure) which, with the help of 27 items allocated to four scales, enables measurement of patient satisfaction with outpatient medical treatment along four dimensions of patient satisfaction. This study examined whether the questionnaire delivers reliable results in an oncological population and whether its application can be extended to inpatient care. Method Required data was collected as part of the PIKKO study. Initially, descriptive statistics and internal consistency (Cronbach’s alpha) of the PREM’s scales were analyzed. In addition, a sub-sample that assessed the same doctor at two consecutive measurement time points was observed with regard to test-retest reliability (Spearman correlation (rs) between both measurement time points). The measurement model of the Qualiskope-A was then examined using confirmatory factor analysis. To test the transferability to inpatient care, measurement invariance with regard to outpatients and inpatients was computed. Results A total of 476 patients was included in the study. Every score of the Qualiskope-A showed a left-skewed distribution in the sample and revealed pronounced ceiling effects. Cronbach’s alpha coefficients were consistently>0,8. Within the test-retest group (n=197), a strong correlation (rs>0,5) was observed between the measurement time points. The fit indices calculated using confirmatory factor analysis showed a good model fit (CFI=0,958; RMSEA=0,026; SRMR=0,040; every factor loadings>0,6). The fit indices, calculated as part of the investigation of measurement invariance, consistently met the defined threshold values. Conclusion The Qualiscope-A shows good reliability in the examined oncological sample. It can be used in both outpatient and inpatient settings (no indications of non-invariance were found). Due to pronounced ceiling effects, however, the item scaling should be revised. Article published online: 07 April 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Diskussion

    by Florian Brandt

  • Ergebnisse

    by Florian Brandt

  • Einleitung

    by Florian Brandt